BioSpace News Archive

Drug Development

Clinical Catch-Up: Good News for BioVie, Regeneron, Relay and More

The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.

September 12, 2022
·
4 min read
·
Vanessa Doctor, RN
FDA

BMS Wins Landmark Approval in Plaque Psoriasis, Avoids Black Box Label

BMS announced that the FDA approved Sotyktu for adults with moderate-to-severe plaque psoriasis, marking this indication’s first oral treatment innovation in nearly a decade.

September 12, 2022
·
3 min read
·
Tristan Manalac
Drug Development

Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO

Regeneron’s oncology strategy is centered around improving checkpoint inhibitor treatments with combination therapies, according to a pipeline overview presented Monday morning.

September 12, 2022
·
2 min read
·
Mark Terry
Young Oncologists Gain Resources, Mentorship at ESMO Congress

Young oncologists arguably stand to gain the most at ESMO by having the opportunity to discuss industry news and network with the most experienced doctors and professionals in their field.

September 12, 2022
·
3 min read
·
Kaley Lefevre
Business

Pretzel Therapeutics Launches with $72M to Advance Mitochondrial Therapies

Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.

September 12, 2022
·
3 min read
·
Tristan Manalac
Drug Development

Novartis Shutters Sandoz Plant, Eyes Liver Cancer and Hidradenitis Suppurativa Approvals

Novartis has had a busy few days, announcing plans to shutter a Sandoz plant, a $300 million infrastructure investment, and Cosentyx, Kisqali and Tislelizumab readouts.

September 12, 2022
·
5 min read
·
Mark Terry
Business

White House Taps Ginkgo Bioworks Vet to Helm New Health Research Organization

President Joe Biden tapped Ginkgo Bioworks veteran Renee Wegrzyn to helm the recently-established Advanced Research Projects Agency for Health (ARPA-H).

September 12, 2022
·
3 min read
·
Alex Keown
Drug Development

ESMO 2022: AstraZeneca Presents Positive Long-Term Tagrisso and Imfinzi Data

AstraZeneca presented data showing Imfinzi and Tagrisso boosted survival chances for patients in different forms of lung cancer at ESMO on Monday.

September 12, 2022
·
4 min read
·
Alex Keown
Drug Development

ESMO 2022: Amgen, Regeneron, GRAIL and More Provide Updates

It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.

September 12, 2022
·
5 min read
·
Mark Terry
Drug Development

Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Can-Fite BioPharma Ltd. announced today that Dr. Kim A. Papp, MD, PhD, presented new data from the Company’s recently completed Phase III COMFORT™ study.

September 12, 2022
·
9 min read